Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients

Genomic rearrangement in anaplastic lymphoma kinase (ALK) gene occurs in 3−7% of patients with non-small-cell lung cancer (NSCLC). The detection of this alteration is crucial as ALK positive NSCLC patients benefit from ALK inhibitors, which improve both the patient's quality of life and overall...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sánchez-Herrero Estela, Provencio Mariano, Romero Atocha
Formato:	article
Lenguaje:	EN ES
Publicado:	De Gruyter 2020
Materias:	anaplastic lymphoma kinase circulating free dna exosomes liquid biopsy non-small-cell lung cancer tyrosine kinase inhibitors Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/5adcc9d796aa44beae1ace9bc24a82b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5adcc9d796aa44beae1ace9bc24a82b4
record_format	dspace
spelling	oai:doaj.org-article:5adcc9d796aa44beae1ace9bc24a82b42021-12-05T14:10:38ZClinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients2628-491X10.1515/almed-2019-0019https://doaj.org/article/5adcc9d796aa44beae1ace9bc24a82b42020-03-01T00:00:00Zhttps://doi.org/10.1515/almed-2019-0019https://doaj.org/toc/2628-491XGenomic rearrangement in anaplastic lymphoma kinase (ALK) gene occurs in 3−7% of patients with non-small-cell lung cancer (NSCLC). The detection of this alteration is crucial as ALK positive NSCLC patients benefit from ALK inhibitors, which improve both the patient's quality of life and overall survival (OS) compared to traditional chemotherapy.Sánchez-Herrero EstelaProvencio MarianoRomero AtochaDe Gruyterarticleanaplastic lymphoma kinasecirculating free dnaexosomesliquid biopsynon-small-cell lung cancertyrosine kinase inhibitorsMedical technologyR855-855.5ENESAdvances in Laboratory Medicine, Vol 1, Iss 1, Pp 7-30 (2020)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	anaplastic lymphoma kinase circulating free dna exosomes liquid biopsy non-small-cell lung cancer tyrosine kinase inhibitors Medical technology R855-855.5
spellingShingle	anaplastic lymphoma kinase circulating free dna exosomes liquid biopsy non-small-cell lung cancer tyrosine kinase inhibitors Medical technology R855-855.5 Sánchez-Herrero Estela Provencio Mariano Romero Atocha Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
description	Genomic rearrangement in anaplastic lymphoma kinase (ALK) gene occurs in 3−7% of patients with non-small-cell lung cancer (NSCLC). The detection of this alteration is crucial as ALK positive NSCLC patients benefit from ALK inhibitors, which improve both the patient's quality of life and overall survival (OS) compared to traditional chemotherapy.
format	article
author	Sánchez-Herrero Estela Provencio Mariano Romero Atocha
author_facet	Sánchez-Herrero Estela Provencio Mariano Romero Atocha
author_sort	Sánchez-Herrero Estela
title	Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
title_short	Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
title_full	Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
title_fullStr	Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
title_full_unstemmed	Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
title_sort	clinical utility of liquid biopsy for the diagnosis and monitoring of eml4-alk nsclc patients
publisher	De Gruyter
publishDate	2020
url	https://doaj.org/article/5adcc9d796aa44beae1ace9bc24a82b4
work_keys_str_mv	AT sanchezherreroestela clinicalutilityofliquidbiopsyforthediagnosisandmonitoringofeml4alknsclcpatients AT provenciomariano clinicalutilityofliquidbiopsyforthediagnosisandmonitoringofeml4alknsclcpatients AT romeroatocha clinicalutilityofliquidbiopsyforthediagnosisandmonitoringofeml4alknsclcpatients
_version_	1718371901911334912

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients

Ejemplares similares